Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated Type 2 Diabetes Mellitus
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of present study were to compare plasma adiponectin isoform status, their bioactivities newly diagnosed Chinese with healthy volunteer.
| Condition |
|---|
|
Diabetes Mellitus |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated T2DM Patients in Chinese Population |
- plasma adiponectin concentration, isoform distribution and activity. [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 week ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
blood，abdominal fat tissue
| Estimated Enrollment: | 300 |
| Study Start Date: | May 2010 |
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
T2DM patients
newly diagnosed T2DM patients and untreated with any drugs.
|
| Non-diabetic Control Group |
Detailed Description:
Adiponectin, circulates as trimer, hexamer and high molecular weight form (HMW) in human blood, is a promising biomarker for indication diabetes and cardiovascular disease. Both adiponectin complexes concentration and their bioactivities are decreased in pathological state. Disulfide-bond A oxidoreductase-like protein (DsbA-L) is a key regulator for adiponectin biosynthesis and its expression level is down-regulated in obese mice and humans. However, the alteration of circulating adiponectin multimers distribution, their bioactivities and adiponectin regulator, DsbA-L level, in newly diagnosed Chinese type 2 diabetes patients are unknown. The objective of present study were to compare plasma adiponectin isoform status, their bioactivities and DsbA-L concentration in newly diagnosed Chinese with healthy volunteer.
Eligibility| Ages Eligible for Study: | 30 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
This study enrolls a group of 30-70years patients from primary care clinic who have diabetes history within 12 months and without taking any treatment.
Inclusion Criteria:
- Having a diabetic history within 12 months
- BMI smaller than 30kg/m2
Exclusion Criteria:
- Having any kinds of treatment affecting glucose
- pregnant
- uncontrolled hypertension, active cardiac disease, or other major liver, kidney disease
Contacts and Locations| Contact: Ling Tao, M.D Ph.D | +86-15002955798 | lingtao2006@gmail.com |
| China, Shaanxi | |
| Xijing Hospital | Recruiting |
| Xi'an, Shaanxi, China, 710032 | |
| Contact: Ling Tao, MD,PhD +86-15002955798 lingtao2006@gmail.com | |
| Principal Investigator: | Ling Tao, M.D Ph.D | Department of Cardiology of Xijing Hospital, Fourth Military Medical University |
More Information
No publications provided
| Responsible Party: | Ling Tao, Department of Cardiology of Xijing Hospital; Fourth Military Medical University |
| ClinicalTrials.gov Identifier: | NCT01372852 History of Changes |
| Other Study ID Numbers: | xjyy110501 |
| Study First Received: | June 11, 2011 |
| Last Updated: | June 13, 2011 |
| Health Authority: | China: Food and Drug Administration |
Keywords provided by Xijing Hospital:
|
Diabetes mellitus |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013